Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
94.2M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
+626K
-
Total reported value, excl. options
-
$503M
-
Value change
-
+$19.1M
-
Number of buys
-
26
-
Number of sells
-
-19
-
Price
-
$29.99
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) as of Q4 2018
57 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock as of Q4 2018.
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 94.2M outstanding shares and own 17.81% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (3.79M shares), FMR LLC (2.94M shares), PERCEPTIVE ADVISORS LLC (2.59M shares), ORBIMED ADVISORS LLC (1.91M shares), RA CAPITAL MANAGEMENT, LLC (1.88M shares), BlackRock Inc. (693K shares), JANUS HENDERSON GROUP PLC (530K shares), PRICE T ROWE ASSOCIATES INC /MD/ (434K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (290K shares), and Vanguard Group Inc (273K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.